This is a news story, published by Investor's Business Daily, that relates primarily to Gilead Sciences news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Gilead stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Gilead Sciences news, earnings news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
GileadInvestor's Business Daily
•
86% Informative
Gilead Sciences ( GILD ) reported adjusted earnings of $ 2.01 per share on $6.95 billion in second-quarter sales.
The biotech company maintained its outlook for $27.1 billion in product sales for the year .
Analysts polled by FactSet expected $ 3.76 earnings per share for the quarter .
VR Score
90
Informative language
90
Neutral language
82
Article tone
formal
Language
English
Language complexity
25
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
3
Affiliate links
no affiliate links